RegenLife Centers · Physician-led care
Stress and Chronic Pain
How Cortisol Drives Inflammation
Published on November 22nd, 2026


The 38-year-old who wakes at 3 a.m. with a jaw clenched so tightly she needs a moment to consciously release it, who has explained to three different physicians that her headaches appear every time a deadline approaches, that her lower back goes out in the week before any significant stressful event, that the fibromyalgia she was diagnosed with after two years of normal blood panels seems to worsen in direct proportion to the stress level she cannot document on any intake form, who was told that stress is a normal part of life and her pain management should focus on physical therapy, that the connection she observes between her anxiety and her body's pain response is understandable but not something medicine can address specifically, and who never learned that her cortisol, the hormone her body produces in response to every perceived threat, deadline, or argument, has been running in a state of chronic dysregulation that is actively suppressing the anti-inflammatory system her body depends on to silence the pain signals her nervous system is generating: this patient has not been told the complete biological story.
Stress and chronic pain share a mechanism that is neither purely psychological nor purely physical. It is a neuroendocrine cascade in which the cortisol system, designed for brief mobilization, becomes chronically dysregulated and loses its capacity to silence inflammation, calibrate pain thresholds, and modulate the nervous system responses that determine whether pain signals amplify or resolve. Stress and chronic pain are not separate problems that happen to coexist; they are interlocked biological processes in which cortisol dysregulation and neuroinflammation sustain each other in a feedback loop that standard care rarely characterizes and almost never addresses at the root. At RegenLife Centers for Integrative Pain & Weight Management, the evaluation of chronic pain begins not with the location of the pain but with the hormonal, inflammatory, and gut-based drivers that determine why pain signals are amplifying rather than resolving, and cortisol is one of the most consistently implicated and consistently underdiagnosed of those drivers.
Ethnic female student in casual wear sitting at table with laptop and notebook and grimacing from migraine while doing homework during distance learningKey Takeaways
- 24.3% of U.S. adults have chronic pain, and 23.8% of those experience persistent anxiety or depression: a co-occurrence rate consistent with the shared neuroendocrine mechanism connecting stress and pain rather than coincidental comorbidity
- Cortisol is the body's primary anti-inflammatory hormone: in acute stress it suppresses NF-κB, IL-6, and TNF-α effectively; but in chronic stress, glucocorticoid receptor downregulation produces cortisol resistance, leaving inflammation unchecked and pain amplified
- Central sensitization: the process by which the nervous system rewires itself to amplify pain signals, is driven in part by neuroinflammation that dysregulated cortisol can no longer suppress, creating a self-reinforcing loop of stress, inflammation, and heightened pain perception
- The DUTCH Complete, GI-MAP, and high-sensitivity inflammatory markers characterize the HPA axis dysfunction, gut dysbiosis, and systemic inflammatory burden that together explain why a specific patient's pain is not resolving: and targeted functional medicine intervention addresses these mechanisms rather than the symptoms they produce
Understanding Stress and Chronic Pain: The Cortisol Connection
What Cortisol Is Designed to Do
Cortisol is not a villain. It is a tool that evolution calibrated for emergencies. Released from the adrenal cortex in response to hypothalamic CRH (corticotropin-releasing hormone) and pituitary ACTH (adrenocorticotropic hormone), a cascade known as the HPA axis, cortisol mobilizes glucose for immediate energy, suppresses digestive and reproductive functions that are nonessential in a crisis, and critically, dampens the immune response. In acute stress, cortisol's anti-inflammatory function is protective: it binds glucocorticoid receptors (GRs) in immune cells, blocks the NF-κB pathway, the master regulator of pro-inflammatory gene expression, and suppresses the production of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), the cytokines that drive tissue inflammation. When the stressor resolves, cortisol levels decline, the immune system resumes normal surveillance, and the HPA axis returns to baseline.
This recovery arc, the key feature of adaptive stress response, is exactly what chronic stress eliminates. When stress is not brief and bounded but sustained, recurring, or psychologically inescapable, the HPA axis cannot complete its return to baseline. Cortisol levels remain elevated not because the threat is still acute but because the stress signal never fully turns off, and the biological consequences of this sustained state are categorically different from those of the acute stress response it was designed to mimic.
How Chronic Stress Breaks the Anti-Inflammatory System
The central mechanism linking chronic stress to chronic inflammation is cortisol resistance: the progressive downregulation of glucocorticoid receptors (GRs) on immune cells in response to chronic cortisol exposure. When cells are bathed in cortisol for weeks or months rather than hours, they reduce the number and sensitivity of the receptors through which cortisol acts, a compensatory adaptation with catastrophic downstream consequences. A 2023 review in Cells (MDPI) confirmed that chronic cortisol exposure disrupts glucocorticoid receptor function, leaving immune cells unable to receive cortisol's anti-inflammatory signal even when cortisol is present in circulation.
The practical consequence: a patient whose morning blood cortisol reads "within normal limits" may simultaneously have immune cells that are functionally deaf to cortisol's anti-inflammatory instructions, meaning NF-κB continues to drive inflammatory gene expression, IL-6 and TNF-α continue to be produced, and the inflammatory signaling that generates and sustains pain continues without the cortisol brake that would ordinarily silence it. This is the mechanism by which chronic stress in the absence of any tissue injury produces chronic pain, not through psychological amplification of signals but through the failure of the body's own anti-inflammatory architecture.
HPA axis dysregulation itself does not follow a single pattern. A 2025 systematic review published in ScienceDirect synthesizing data from multiple studies found that chronic primary pain is associated with both elevated and reduced basal cortisol levels, reflecting different stages of HPA axis adaptation, from early hyperactivation to later blunting as the axis exhausts its regulatory capacity. What is consistent across both patterns is abnormal cortisol rhythm: a disrupted cortisol awakening response, a flattened diurnal curve, and impaired reactivity to new stressors, all of which correlate with heightened pain sensitivity and reduced pain tolerance.
Neuroinflammation and Central Sensitization: How Stress Rewires the Pain System
Lab technician using a centrifuge for blood analysis in a modern laboratory settingWhat Central Sensitization Is and Why Stress Drives It
Central sensitization is the process by which the central nervous system undergoes neuroplastic changes that amplify its response to both painful and non-painful stimuli, the mechanism by which a person who once felt pain only at the site of injury begins to feel pain across broader areas, at lower stimulus thresholds, and for longer durations than the original injury would explain. A 2023 review in the Cleveland Clinic Journal of Medicine describes central sensitization as the pathophysiologic process underlying fibromyalgia, chronic low back pain, migraine, and irritable bowel syndrome, conditions in which patients have pain that standard imaging and structural evaluation cannot explain.
The role of chronic stress in central sensitization is direct and mechanistically documented. Research published in PMC confirms that neuroinflammation drives central sensitization through glial cell activation: microglia and astrocytes in the spinal cord and brain release pro-inflammatory cytokines including IL-6, IL-1β, and TNF-α that sensitize dorsal horn neurons, lower pain thresholds, and expand the receptive fields of pain-processing neurons. Cortisol, when functioning normally, modulates this neuroinflammatory cascade. When cortisol resistance or HPA axis hypofunction eliminates this modulation, the neuroinflammatory cascade that produces central sensitization runs without its primary regulatory brake.
The clinical implication is that the patient who reports widespread pain, pain that spreads beyond the original injury site, or pain that persists long after tissues have healed is not experiencing psychological amplification, she is experiencing a measurable neurobiological change that chronic stress has induced by removing the cortisol-mediated anti-inflammatory regulation the nervous system depends on.
The BDNF-Cortisol Axis: How Stress Hormones Rewire Pain Circuits
A 2024 review in PMC examining brain-derived neurotrophic factor (BDNF) and central sensitization identified a second mechanism through which stress hormones alter pain processing: BDNF upregulation in the dorsal horn of the spinal cord, driven by chronic inflammatory signaling. BDNF amplifies the activity of NMDA receptors, the glutamate receptors whose overactivation is a defining feature of central sensitization, and reduces the effectiveness of inhibitory interneurons that would otherwise dampen pain signal transmission. Elevated cortisol in early HPA hyperactivation promotes BDNF expression in pain-processing regions; HPA hypofunction in later chronic stress stages removes the cortisol that would normally limit this expression. Either direction of cortisol dysregulation contributes to the BDNF-mediated sensitization that makes the nervous system progressively less able to filter and downregulate pain signals.
This is the neurological architecture that explains a clinical observation familiar to every chronic pain patient but rarely explained adequately in standard care: the stress of an argument, a difficult week at work, or an emotionally demanding situation will predictably worsen pain that was managed the day before, not because emotional distress "causes" pain through psychosomatic mechanisms, but because the acute cortisol spike from psychological stress, in an already-dysregulated HPA axis, further amplifies the neuroinflammatory signaling that central sensitization requires to sustain itself.
The Gut-Brain-Cortisol Axis: How Stress Drives Inflammation from the Inside
Chronic Stress, Dysbiosis, and Intestinal Permeability
The stress-pain connection extends beyond the brain and spinal cord into the gastrointestinal system through a pathway that standard pain management does not assess but that functional medicine evaluation identifies in a significant proportion of chronic pain patients. A 2024 systematic review and meta-analysis published in Frontiers in Immunology confirmed gut dysbiosis in patients with chronic pain, specifically, reduced populations of anti-inflammatory butyrate-producing bacteria and increased gram-negative bacterial species whose outer membranes contain lipopolysaccharide (LPS), a potent inflammatory trigger.
Chronic stress activates the HPA axis and simultaneously activates the sympathetic nervous system, both of which independently alter gut microbiome composition. Elevated cortisol increases gastrointestinal permeability, loosening the tight junctions that maintain intestinal barrier integrity, allowing bacterial components including LPS to enter systemic circulation. LPS binds to toll-like receptor 4 (TLR4) on immune cells, triggering NF-κB activation and the production of exactly the pro-inflammatory cytokines, IL-6, TNF-α, IL-1β, that cortisol resistance has already failed to suppress. The gut, under chronic stress, becomes a second source of the inflammatory signal that the dysregulated cortisol system can no longer silence.
A 2023 review in Frontiers in Endocrinology confirmed bidirectionality in this system: gut microbiota composition directly influences HPA axis activity through vagal signaling, short-chain fatty acid production, and microbial metabolite signaling, meaning that the dysbiosis chronic stress induces further dysregulates the HPA axis that caused the dysbiosis in the first place. Research published in PMC in 2025 on the gut-brain axis and chronic pain documents this as a pathological feedback loop: stress disrupts the gut, the disrupted gut signals the brain to amplify stress responses, and those amplified stress responses further degrade both HPA axis regulation and gut barrier function. The gut health and chronic pain connection at RegenLife reflects this mechanistic understanding.
Why the Gut Is Relevant to Pain That Seems to Have Nothing to Do with Digestion
The patient whose chronic back pain, headaches, or fibromyalgia has no obvious gastrointestinal component, who does not have IBS or reflux and does not think of herself as having a "gut problem", may nonetheless have the intestinal permeability, dysbiosis, and LPS-driven systemic inflammation that is sustaining her pain's neuroinflammatory substrate. Gut dysbiosis does not require digestive symptoms to produce systemic inflammation; the inflammatory signals LPS generates are systemic, not local, and their neurological manifestations, central sensitization, amplified pain signaling, fatigue, cognitive impairment, are indistinguishable from those produced by any other source of chronic low-grade inflammation.
Functional Medicine Testing for Stress-Driven Chronic Pain
A woman with back pain consulting her physician in a modern clinical settingWhy Standard Labs Miss the Stress-Cortisol-Pain Connection
A morning serum cortisol that returns within normal reference ranges tells a clinician approximately this: the patient's adrenal glands produced cortisol at some point within the range of the general population at the time of blood draw. It does not characterize the diurnal pattern, the cortisol awakening response, the metabolite production rate, the degree of glucocorticoid receptor sensitivity, or the relationship between cortisol output and the inflammatory markers driving the patient's pain. The standard evaluation for chronic pain, imaging, inflammatory markers, and basic labs, is designed to identify structural pathology and gross metabolic disruption, not the neuroendocrine dysregulation that functional medicine evaluation characterizes.
The diagnostic services evaluation at RegenLife for stress-driven chronic pain includes:
- DUTCH Complete: dried urine assessment of free cortisol and cortisol metabolites across the day, the cortisol awakening response (CAR), DHEA-S, sex hormones, melatonin, and organic acid markers reflecting neurotransmitter and oxidative stress status. The diurnal pattern, not a single value, is what distinguishes HPA hypofunction from hyperactivation, and the DUTCH Complete provides the multi-point characterization that a spot draw cannot
- GI-MAP stool analysis: quantifying zonulin (direct marker of intestinal permeability), commensal and pathogenic bacterial populations, butyrate-producing species, and inflammatory markers characterizing the gut-sourced inflammatory contribution to systemic and neurological inflammation
- High-sensitivity CRP and inflammatory cytokines: quantifying the systemic inflammatory burden that correlates with pain severity and responds to targeted intervention; an hs-CRP below 1 mg/L is the functional target for pain reduction, not simply "within normal limits"
- Full thyroid panel: free T3, free T4, reverse T3, and thyroid antibodies, because the chronic stress-induced cortisol dysregulation that impairs pain resolution also drives impaired T4-to-T3 conversion, producing the cellular hypothyroid state that standard TSH alone will not detect
- Micronutrient assessment: characterizing magnesium, vitamin D, B12, and zinc status, each of which independently modulates inflammatory signaling, HPA axis function, and pain threshold
The Cortisol Awakening Response as a Pain Biomarker
The cortisol awakening response (CAR), the sharp rise in cortisol that occurs in the first 30–45 minutes after waking, is emerging as one of the most clinically informative markers in HPA axis evaluation for pain patients. An elevated CAR has been associated with ongoing pain, glycemic dysregulation, and early-stage HPA hyperactivation; a blunted or absent CAR reflects HPA axis exhaustion associated with chronic fatigue, persistent pain, and reduced stress reactivity. Research from the DUTCH team confirms that both patterns appear in chronic pain patients, and that knowing which pattern is present determines whether interventions should support cortisol production, improve cortisol clearance, or restore receptor sensitivity.
This is the clinical specificity that functional evaluation provides: not "your cortisol is abnormal" but "your cortisol awakening response is absent, your diurnal slope is flat, and your cortisol metabolites suggest impaired clearance rather than reduced production", a characterization that points to a specific mechanism and a specific therapeutic target. The hormone testing available through RegenLife includes the adrenocortical stress profile and CAR assessment that characterize this dysregulation pattern before any treatment protocol is selected.
The Functional Medicine Treatment Approach: Interrupting the Stress-Inflammation-Pain Cycle
Assortment of supplement capsules and vitamins representing targeted nutritional support for stress and inflammationHPA Axis Support and Adaptogenic Therapy
The interventions with the strongest mechanistic rationale for HPA axis dysregulation in chronic pain address the cortisol regulation system directly, not by suppressing or forcing cortisol production but by modulating the HPA axis's response to stress signals. Adaptogenic herbs, specifically ashwagandha (Withania somnifera) and Rhodiola rosea, are among the most evidence-supported interventions for HPA axis recalibration. Ashwagandha's active constituents (withanolides) have been shown in multiple randomized controlled trials to reduce cortisol by up to 30%, improve stress resilience markers, and reduce self-reported anxiety and fatigue. Rhodiola targets the HPA axis through inhibition of the enzyme that degrades monoamine neurotransmitters, reducing the stress-induced depletion of serotonin and dopamine that exacerbates cortisol dysregulation.
These are not interchangeable recommendations to "take an adaptogen", the specific herb, dose, and timing are calibrated to the patient's cortisol pattern. A patient with a blunted CAR and HPA hypofunction requires different support than one with an elevated CAR and early-stage hyperactivation; the DUTCH Complete's characterization of the specific dysregulation pattern is the prerequisite for selecting the appropriate adaptogenic intervention. The adrenal fatigue treatment approach at RegenLife extends beyond adaptogens to phosphatidylserine, a phospholipid with direct evidence for reducing the cortisol response to stress, vitamin C, which is concentrated in adrenal tissue and consumed in proportion to cortisol production, and B5 (pantothenic acid), a required cofactor for adrenal steroidogenesis that is frequently depleted in chronically stressed patients.
Gut Restoration and the Inflammatory Substrate
Addressing gut-sourced inflammation in stress-driven chronic pain requires targeted microbiome restoration with the specific additions that address the HPA-gut bidirectional relationship. Butyrate-producing prebiotic fibers, inulin, resistant starch, and fermentable fiber from diverse plant sources, restore the Faecalibacterium prausnitzii and Roseburia populations whose absence allows intestinal permeability to persist. When these populations are restored, butyrate production rises, tight junction integrity improves, LPS translocation into systemic circulation decreases, and the gut-sourced NF-κB activation sustaining the patient's systemic inflammation is reduced at its source.
L-glutamine supports tight junction repair directly as the primary fuel source for intestinal epithelial cells; zinc carnosine has documented evidence for intestinal permeability reduction; probiotic strains including Lactobacillus rhamnosus GG and Bifidobacterium longum reduce the inflammatory cytokine production that stress-altered microbiomes sustain. The dietary framework, diverse plant fiber intake, fermented foods, elimination of ultra-processed foods that selectively feed pro-inflammatory Enterobacteriaceae, addresses the gut-sourced inflammatory substrate in parallel with the HPA axis interventions that address the neuroendocrine driver.
Nutritional, Hormonal, and Lifestyle Integration
Magnesium deficiency, present in an estimated 68% of the American population and consistently demonstrated in chronic pain and fibromyalgia patients, is mechanistically relevant to both HPA axis dysregulation and pain amplification. Magnesium is a required cofactor for HPA axis hormone synthesis, a natural NMDA receptor antagonist that reduces the glutamate-driven neuronal excitability underlying central sensitization, and an inhibitor of substance P release, the neuropeptide that transmits pain signals from peripheral to central neurons. Magnesium glycinate or malate at therapeutic doses addresses the cofactor deficit that compounds both stress reactivity and pain sensitivity in these patients.
The hormone therapy at RegenLife addresses the hormonal environment in which the cortisol-inflammation-pain cycle operates. Testosterone deficiency in both men and women independently amplifies inflammatory cytokine production and reduces pain threshold, and the chronic stress that dysregulates cortisol also suppresses gonadotropin-releasing hormone, reducing testosterone and estrogen production through the same HPA axis disruption. Patients whose pain is driven partly by sex hormone deficiency do not achieve full resolution through cortisol support alone; the comprehensive hormonal evaluation at RegenLife identifies this contributor before treatment is selected.
Sleep optimization is not a lifestyle adjunct to this treatment plan. It is a primary mechanism. Sleep is the period during which cortisol reaches its daily nadir, the HPA axis undergoes restoration, and neuroinflammatory clearance occurs through the glymphatic system. Chronic pain disrupts sleep; disrupted sleep dysregulates cortisol further; dysregulated cortisol amplifies pain, a three-way cycle that cannot be broken by treating only one component. Melatonin calibration, blue light management, and sleep architecture optimization are clinical interventions in this framework because normalizing nocturnal cortisol nadir is what HPA axis recovery depends on.
The lifestyle medicine and behavioral health protocols at RegenLife address the psychological drivers of HPA axis activation, not because the pain is psychological but because the stress signals activating the HPA axis are, for many patients, primarily driven by psychological stressors that mind-body interventions address more effectively than any supplement can. Mindfulness-based stress reduction (MBSR) has documented evidence for reducing the cortisol awakening response, lowering inflammatory cytokine levels, and reducing chronic pain scores, not through belief or placebo but through measurable reductions in the HPA axis activation that was sustaining the inflammatory cascade.
The Integrated Evaluation at RegenLife: Stress and Chronic Pain in Cincinnati
The patient whose chronic pain has been managed with NSAIDs, physical therapy, and the instruction to "reduce stress", without any evaluation of her cortisol pattern, her inflammatory cytokine burden, her gut microbiome integrity, or her hormonal status, has not received incomplete treatment; she has received treatment designed for a different kind of pain. Structural pain management addresses structural causes of pain. Stress-driven, cortisol-mediated, neuroinflammatory chronic pain has biological drivers that are not visible on imaging, not detectable by standard panels, and not responsive to mechanical interventions applied without the root-cause evaluation that identifies them.
The evaluation at RegenLife begins with the question that standard care rarely asks: not "where is the pain?" but "why is this patient's nervous system amplifying pain signals and failing to resolve them?", and answers it through HPA axis characterization, gut dysbiosis assessment, inflammatory marker quantification, and hormonal evaluation that together map the biological drivers of a specific patient's presentation. The interventional pain procedures and regenerative program at RegenLife address the structural and tissue-level components of pain; the functional evaluation ensures the neuroendocrine and inflammatory substrate those procedures operate within is not continuing to drive pain independent of the tissue pathology being treated.
Contact RegenLife Centers to schedule an evaluation or ask which service fits your needs.
Frequently Asked Questions
Find answers to common questions
Ready to Learn More?
To learn more and to find out if you might be a good candidate at RegenLife, schedule a consultation with our team today.
About the Author

Caitlyn Benton, Research Manager at RegenLife
As Research Manager, Caitlyn Benton oversees the strategic planning and execution of clinical research projects, ensuring all studies adhere to the highest regulatory and ethical standards. With expertise in protocol development and data monitoring, she coordinates multidisciplinary teams to ensure the integrity of our clinical research programs and the accuracy of the insights shared with our patients.
Reviewed and Approved by

Dr. Zeeshan Tayeb, Medical Director at RegenLife
Interventional Spine, Pain, and Sports Medicine Dr. Zeeshan Tayeb, MD is board-certified in Pain Medicine and Physical Medicine & Rehabilitation, with specialized fellowship training in interventional spine, pain, and sports medicine. He sees patients at Pain Specialists of Cincinnati/RegenLife in Cincinnati, Ohio. Dr. Tayeb's background in physical medicine and rehabilitation has provided the foundation for his comprehensive approach to treating the whole person. Dr. Tayeb has done extensive training and education in both functional and regenerative medicine and specializes in state-of-the-art treatments, including laser therapies, PRP and stem-cell injections, and nutritional and hormonal optimization.
Disclaimer:
As a service to our readers, RegenLife provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
Stay Updated With Our Latest News
Check back regularly for new articles and updates about pain management treatments, practice news, and health tips from our team of specialists.
Get In Touch
Same-week consults. Real follow-through.
Tell us what's going on. A coordinator will follow up during office hours to help book your visit.
Choose the clinic that works for you.
Most new patients can be seen within the same week.
We accept most major insurance plans